BioCentury
ARTICLE | Company News

AbbVie, BI enter immunology deal

March 8, 2016 1:22 AM UTC

AbbVie Inc. (NYSE:ABBV) and Boehringer Ingelheim GmbH (Ingelheim, Germany) partnered to develop and commercialize a pair of Boehringer's immunology candidates, including BI 655066, a mAb against IL-23 that is in Phase III for moderate to severe plaque psoriasis, and BI 655064, an anti-CD-40 antibody that is in Phase I.

Boehringer will receive $595 million up front and is eligible for undisclosed milestones and royalties. ...